Aspire expands oncology portfolio with prostate cancer hormone therapy

Aspire Pharma Limited has reaffirmed its commitment to combating prostate cancer by adding leuprorelin acetate as a branded generic to its oncology
portfolio. This move solidifies Aspire's position as a leading specialty generics enterprise.

Leuprorelin acetate is a hormone therapy recommended for patients with high-risk localized, locally advanced, and metastatic prostate cancer. It serves as an
alternative to surgical castration for locally advanced cases. A pre-filled syringe containing 11.25mg of leuprorelin acetate (equivalent to 10.72 mg leuprorelin)
is injected subcutaneously into the abdomen, providing a vital treatment option for patients.

Aspire expands oncology portfolio with prostate cancer hormone therapy

Aspire Pharma Limited has solidified its position as a leading specialty generics enterprise by adding leuprorelin acetate as a branded generic to its
oncology portfolio.

Leuprorelin acetate is hormone therapy recommended for patients with high-risk localised, locally advanced, and metastatic prostate cancer, serving as an
alternative to surgical castration for locally advanced cases.

Used as an alternative to surgical castration for locally advanced prostate cancer, a pre-filled syringe containing 11.25mg of leuprorelin acetate
(equivalent to 10.72 mg leuprorelin) is injected subcutaneously into the abdomen.

The British pharmaceutical company noted that one of its primary objectives is to seek “new investment opportunities” that brings products and companies into
its portfolio, aligning closely with Aspire values and therapeutic focus areas.

Prostate cancer is the most common cancer among men in the UK, with an average of over 52,000 men receiving a diagnosis of prostate cancer annually, as per
Prostate Cancer UK.